Correspondence 0000950170-24-049569 from Oncternal Therapeutics, Inc. (ONCT) (CIK 0001260990)
Oncternal Therapeutics, Inc. (ONCT) (CIK 0001260990)
Date: April 29, 2024 · CIK: 0001260990 · Accession: 0000950170-24-049569
AI Filing Summary & Sentiment
File numbers found in text: 333-277795
Letter
Oncternal Therapeutics, Inc.
12230 El Camino Real, Suite 230
San Diego, California 92130
April 29, 2024
VIA EDGAR
Tyler Howes
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Oncternal Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-277795
To the addressee set forth above:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Oncternal Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 1, 2024, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Anthony Gostanian of Latham & Watkins LLP at (858) 523-3969. Thank you for your assistance and cooperation in this matter.
Sincerely,
ONCTERNAL THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 230 San Diego, California 92130 April 29, 2024 VIA EDGAR Tyler Howes Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncternal Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-277795 To the addressee set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Oncternal Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 1, 2024, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Anthony Gostanian of Latham & Watkins LLP at (858) 523-3969. Thank you for your assistance and cooperation in this matter. Sincerely, ONCTERNAL THERAPEUTICS, INC. By: /s/ Chase Leavitt Chase Leavitt General Counsel cc: James B. Breitmeyer, M.D., Ph.D., Oncternal Therapeutics, Inc. Matthew T. Bush, Latham & Watkins LLP |US-DOCS\150446178.1||